Dánsko - dánština - Lægemiddelstyrelsen (Danish Medicines Agency)

sandoz a/s - rivastigmin - depotplastre - 9,5 mg/24 timer

Dánsko - dánština - Lægemiddelstyrelsen (Danish Medicines Agency)

fresenius kabi ab - fiskeolie, rig på omega-3-syrer, olivenolie, renset, soyaolie, triglycerider, middelkædelængde - infusionsvæske, emulsion - 200 mg/ml

Dánsko - dánština - Lægemiddelstyrelsen (Danish Medicines Agency)

aristo pharma gmbh - alfacalcidol - kapsler, bløde - 0,5 mikrogram

Dánsko - dánština - Lægemiddelstyrelsen (Danish Medicines Agency)

aristo pharma gmbh - alfacalcidol - kapsler, bløde - 1 mikrogram

Dánsko - dánština - Lægemiddelstyrelsen (Danish Medicines Agency)

stragen nordic a/s - desogestrel, ethinylestradiol - tabletter - 0,15+0,03 mg

Dánsko - dánština - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - fusidinsyre, hydrocortisonacetat - creme - 10+20 mg/g

Dánsko - dánština - Lægemiddelstyrelsen (Danish Medicines Agency)

glenmark arzneimittel gmbh - mometasonfuroat - creme - 1 mg/g

Evropská unie - dánština - EMA (European Medicines Agency)

amgen europe b.v. - blinatumomab - forløbercellelimfoblastisk leukæmi-lymfom - antineoplastiske midler - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.

Evropská unie - dánština - EMA (European Medicines Agency)

pfizer europe ma eeig - bosutinib (som monohydrat) - leukæmi, myeloid - antineoplastic agents, protein kinase inhibitors - bosulif er indiceret til behandling af voksne patienter med nyligt diagnosticeret kronisk fase (cp) philadelphia-kromosom-positiv kronisk myelogenous leukæmi (ph+ cml). cp, accelereret fase (ap), og blast fase (bp) ph+ cml, der tidligere er behandlet med en eller flere tyrosin kinase inhibitor(s) [tki(s)], og for hvem imatinib, nilotinib og dasatinib er ikke anset som egnede behandlingsmuligheder.

Evropská unie - dánština - EMA (European Medicines Agency)

pfizer europe ma eeig - inotuzumab ozogamicin - forløbercellelimfoblastisk leukæmi-lymfom - antineoplastiske midler - besponsa er indiceret som monoterapi til behandling af voksne med recidiveret eller ildfast cd22-positiv b-celleprecursor akut lymfoblastisk leukæmi (all). voksne patienter med philadelphia-kromosom-positiv (ph +) tilbagefalds- eller ildfast b-celleprecursor all skal have mislykket behandling med mindst 1 tyrosinkinasehæmmer (tki).